AssetMark’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
Other funds holding CYTK
AssetMark's CYTK Position: Q3 2026 in Review
AssetMark increased its Cytokinetics (CYTK) stake by 16% in Q3 2026, buying an estimated $60.2K and bringing the position to 5,584 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #1310.
AssetMark first reported a position in CYTK in Q4 2016 and has held it in 11 quarters since. The position peaked at $408K in Q2 2026. 354 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.
- AssetMark held 5,584 shares of Cytokinetics worth $368K as of Q3 2026.
- AssetMark bought 789 Cytokinetics shares in Q3 2026, an estimated $60.2K.
- Cytokinetics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1310 holding.
- AssetMark first reported a position in Cytokinetics in Q4 2016 and has held it in 11 quarters since.
- AssetMark's Cytokinetics position peaked at $408K in Q2 2026.
- 354 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.